Evidence map›Paper›PMID 38668129›Full record

ReviewNeurology international2024

Neurocognitive Impairment and Social Cognition in Parkinson's Disease Patients.

Triantafyllos Doskas, Konstantinos Vadikolias, Konstantinos Ntoskas, George D Vavougios, Dimitrios Tsiptsios, Polyxeni Stamati, Ioannis Liampas, Vasileios Siokas, Lambros Messinis, Grigorios Nasios and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Triantafyllos DoskasDepartment of Neurology, Athens Naval Hospital, 11521 Athens, Greece.
Konstantinos VadikoliasDepartment of Neurology, General University Hospital of Alexandroupoli, 68100 Alexandroupoli, Greece.ORCID 0000-0003-0484-369X
Konstantinos Ntoskas251 Airforce General Hospital, 11525 Athens, Greece.
George D VavougiosDepartment of Neurology, Athens Naval Hospital, 11521 Athens, Greece.ORCID 0000-0002-0413-4028
Dimitrios TsiptsiosDepartment of Neurology, General University Hospital of Alexandroupoli, 68100 Alexandroupoli, Greece.ORCID 0000-0002-1601-8788
Polyxeni StamatiDepartment of Neurology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece.
Ioannis LiampasDepartment of Neurology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece.ORCID 0000-0002-2958-5220
Vasileios SiokasDepartment of Neurology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece.
Lambros MessinisSchool of Psychology, Laboratory of Neuropsychology and Behavioural Neuroscience, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.ORCID 0000-0002-3216-9025
Grigorios NasiosDepartment of Speech and Language Therapy, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.ORCID 0000-0001-7495-6863
Efthimios DardiotisDepartment of Neurology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece.

Funding

Financial support was received from UCB SA for medical writing support services. NA
6 · The paper itself

Abstract

In addition to motor symptoms, neurocognitive impairment (NCI) affects patients with prodromal Parkinson's disease (PD). NCI in PD ranges from subjective cognitive complaints to dementia. The purpose of this review is to present the available evidence of NCI in PD and highlight the heterogeneity of NCI phenotypes as well as the range of factors that contribute to NCI onset and progression. A review of publications related to NCI in PD up to March 2023 was performed using PubMed/Medline. There is an interconnection between the neurocognitive and motor symptoms of the disease, suggesting a common underlying pathophysiology as well as an interconnection between NCI and non-motor symptoms, such as mood disorders, which may contribute to confounding NCI. Motor and non-motor symptom evaluation could be used prognostically for NCI onset and progression in combination with imaging, laboratory, and genetic data. Additionally, the implications of NCI on the social cognition of afflicted patients warrant its prompt management. The etiology of NCI onset and its progression in PD is multifactorial and its effects are equally grave as the motor effects. This review highlights the importance of the prompt identification of subjective cognitive complaints in PD patients and NCI management.

Indexed as

cognitive functioncognitive impairmentParkinson’s diseasesocial cognition

Identifiers

PMID38668129
PMCPMC11054167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.